Hinge Health, Inc.
HNGE
$97.86
-0.50%
Hinge Health, Inc. is a healthcare technology company operating a digital platform for the treatment and prevention of joint and muscle pain, combining AI-powered motion tracking with clinical care pathways to address chronic musculoskeletal (MSK) conditions for members while reducing costs for employer and health-plan clients. The company sits within the Medical-Healthcare Information Services industry and positions itself as a scaled, evidence-based virtual MSK clinic rather than a generic wellness app, differentiating through proprietary patient movement data that underpins its AI models and outcomes reporting. The current investor narrative centers on the company's transition from a high-burn digital-health disruptor to a profitable, cash-generative platform: recent quarterly results showed roughly 53% year-over-year revenue growth, positive GAAP net income, and raised guidance, which has driven a dramatic re-rating since its May 2025 IPO. At the same time, debate persists around whether growth is already priced in, competitive intensity in digital MSK care, and the sustainability of margins as the company scales, with sell-side commentary split between enthusiasm over the AI/data moat and caution on valuation.…
HNGE
Hinge Health, Inc.
$97.86
Related headlines
Investment Opinion: Should I buy HNGE Today?
HNGE merits a Buy rating for growth-oriented investors with a higher risk tolerance. The core thesis is that Hinge Health is a rare digital health company that has achieved both rapid revenue growth (53% YoY) and profitability (20.5% net margin), with a clean balance sheet and strong free cash flow, positioning it to capture a large and underpenetrated digital MSK market. The analyst consensus is 'buy' (mean 1.53) with an average target of $109.31, implying 11.9% upside, though the high target of $140 suggests more significant potential if execution continues.
The supporting evidence is compelling: revenue has grown sequentially for five consecutive quarters (from $139.1M in Q2 2025 to $212.8M in Q2 2026), gross margins have expanded to 86.4%, and the company generated $287.3M in trailing free cash flow. The forward PE of 31.9x is a premium, but it is justified by the growth rate and margin profile; when adjusted for growth (PEG), the valuation is not excessive. The balance sheet is debt-free with $287.7M in cash, and the company is buying back stock ($26.5M in Q2), signaling confidence.
Key risks that could invalidate the thesis include: (1) a slowdown in revenue growth below 40%, which would likely compress the multiple; (2) intensifying competition eroding margins; and (3) a broad market rotation away from high-multiple growth stocks. The rating would upgrade to a strong buy if the stock pulls back to the $85-90 support zone while fundamentals remain intact, or downgrade to a hold if revenue growth decelerates below 30% or if operating margins contract for two consecutive quarters. Relative to its own history, the stock is fairly valued (forward PE of 31.9x vs. historical PE of 37.7x), but it trades at a premium to the broader healthcare sector, reflecting its superior growth and profitability.
Sign up to view all
HNGE 12-Month Price Forecast
HNGE presents a compelling growth story with a rare combination of high revenue growth and profitability. The company's AI-driven digital MSK platform has demonstrated strong traction, and the balance sheet is exceptionally clean. However, the stock's premium valuation and recent 114% YTD run leave little room for error. The base case (55% probability) assumes continued execution with moderating growth, leading to a target range of $105-115. The bull case (25%) hinges on sustained 50%+ growth and multiple expansion, while the bear case (20%) reflects risks of deceleration and de-rating. I would upgrade to high confidence if Q3 results show revenue growth above 50% with expanding margins, and downgrade to neutral if growth falls below 40% or if competitive pressures become evident in customer acquisition costs.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hinge Health, Inc.'s 12-month outlook, with a consensus price target around $110.56 and implied upside of +13.0% versus the current price.
Average Target
$110.56
0 analysts
Implied Upside
+13.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $140
Analyst target range
Coverage is robust for a recent IPO, with 16 analysts covering HNGE and a consensus recommendation of "buy" (recommendation mean of 1.53, where 1.0 is a strong buy). The average price target is $109.31, implying roughly +11.9% upside from the current price of $97.67, with a low target of $90.00 (about -7.9% downside) and a high target of $140.00 (about +43.3% upside); the consensus therefore leans bullish but with the average target only modestly above the current price, suggesting much of the near-term upside has already been captured after the stock's 114% YTD run. The institutional ratings flow is overwhelmingly constructive and stable: recent actions include Baird maintaining Neutral (September 22, 2026), Stifel reiterating Buy (September 8, 2026), and a cluster of Buy/Outperform/Overweight reiterations on August 5, 2026 from Truist, Needham, Citizens, RBC Capital, Evercore ISI, Wells Fargo, and Barclays, with no downgrades in the visible record. The target range of $90 to $140 is relatively wide (a 55.6% spread from low to high), signaling meaningful disagreement about the pace of growth and margin expansion; the high target of $140 likely assumes sustained 50%+ revenue growth, continued margin expansion toward software-like levels, and multiple expansion on the AI/data moat, while the low target of $90 essentially prices in the stock holding current levels or modest multiple compression if growth normalizes. The absence of any recent downgrades and the concentration of reiterations around the August 5 earnings date suggest analysts were reassured by Q2 results and raised guidance, but the Neutral rating from Baird and the Zacks "hold" commentary indicate a meaningful minority view that growth is already priced in, which caps near-term upside and makes execution on upcoming quarters the key catalyst.
Drowning in data?
Find the real signal!
Bulls vs Bears: HNGE Investment Factors
The bull case for HNGE rests on exceptional revenue growth (53% YoY), a dramatic profitability inflection (20.5% net margin), a pristine balance sheet (debt-to-equity 0.021), and a differentiated AI/data moat in digital MSK care. The bear case centers on a premium valuation (31.9x forward PE, 6.26x PS), limited analyst upside (11.9% to average target), intensifying competition, and the stock's history of violent drawdowns (-48% max). Currently, the bull evidence is stronger: the company is executing at a high level, and the recent Q2 beat-and-raise has reinforced confidence. However, the single most important tension is whether HNGE can sustain 50%+ growth as it scales toward $1B in revenue; any deceleration below 40% would likely trigger significant multiple compression given the premium valuation. The resolution of this growth durability question will determine whether the stock continues its ascent or enters a prolonged correction.
Bullish
- Explosive revenue growth at scale: Q2 2026 revenue reached $212.8 million, up 53% year-over-year, with sequential acceleration from $182.3M in Q1. This mid-50s growth on a ~$1B annualized base demonstrates strong product-market fit and scalable unit economics.
- Dramatic margin expansion and profitability: Gross margin expanded from 70.3% in Q2 2025 to 86.4% in Q2 2026, while net margin swung from -413.8% to +20.5%. Q2 2026 net income of $43.7M and operating margin of 19.0% confirm a successful transition to profitable growth.
- Fortress balance sheet with strong FCF: Debt-to-equity is just 0.021, current ratio is 1.47, and trailing twelve-month free cash flow is $287.3M. Q2 2026 operating cash flow of $101.4M with only $1.9M capex yielded $99.6M FCF, funding $26.5M in buybacks and $287.7M cash position.
- AI/data moat in digital MSK: Proprietary patient movement data underpins AI models and outcomes reporting, creating a competitive advantage in the high-growth digital musculoskeletal market. This data flywheel differentiates HNGE from generic wellness apps and supports client retention.
Bearish
- Premium valuation leaves little room for error: Forward PE of 31.9x and PS of 6.26x are rich for a healthcare services company, even one growing at 53%. The stock trades at 97.9% of its 52-week range, and any deceleration could trigger sharp multiple compression.
- Growth already priced in, limited upside: The average analyst target of $109.31 offers only 11.9% upside, and the low target of $90 implies -7.9% downside. The consensus 'buy' rating masks a wide target range ($90-$140), signaling disagreement about the pace of future growth.
- Competitive intensity in digital health: The digital MSK space is increasingly crowded with well-funded competitors. Zacks notes that 'competition in digital health remains fierce,' which could pressure pricing, member acquisition costs, and retention rates over time.
- Historical volatility and drawdown risk: The stock experienced a maximum drawdown of -48.03% over the past year, and the 52-week low of $30.08 is 69.2% below the current price. This extreme volatility underscores the risk of sharp reversals, especially after a 150.6% six-month rally.
HNGE Technical Analysis
HNGE is in a powerful, sustained uptrend, with the current price of $97.67 representing an 84.9% gain over the past year and a 114.4% gain year-to-date, dramatically outperforming the S&P 500's 15.0% one-year and 12.9% YTD returns. The stock is trading at approximately 97.9% of its 52-week range (52-week low of $30.08, 52-week high of $99.73), meaning it is pressed right against its highs and exhibiting classic momentum leadership rather than value positioning. This near-high positioning signals strong trend conviction but also leaves little margin for error, as any disappointment could trigger sharp mean reversion given the extended move off the lows. Recent momentum remains constructive but is decelerating relative to the explosive mid-year phase: the 1-month change is +6.3% and the 3-month change is +16.2%, versus the 6-month change of +150.6%, indicating the steepest part of the advance occurred earlier in 2026. The stock's relative strength versus SPY is positive across all windows (+5.7% over 1 month, +12.9% over 3 months, +133.2% over 6 months), confirming persistent outperformance, though the narrowing 1-month spread suggests the pace of alpha generation is cooling as the stock consolidates near $95-98. Key technical support sits at the 52-week low area of $30.08, with intermediate support likely around the $85-88 zone where the stock repeatedly found buyers in August and September; resistance is the 52-week high of $99.73, and a decisive breakout above $100 would signal continuation of the primary uptrend. A breakdown below the $85 support shelf would warn of a deeper correction, while the maximum drawdown of -48.03% over the past year is a reminder that this name can correct violently despite its uptrend; with a short ratio of 2.64 and volume of roughly 977,494 shares, liquidity is adequate but not deep, and the absence of a reported beta means volatility should be gauged from the stock's own 48% drawdown history rather than a market-relative coefficient.
Beta
—
—
Max Drawdown
-48.0%
Largest decline past year
52-Week Range
$30-$100
Price range past year
Annual Return
+91.3%
Cumulative gain past year
| Period | HNGE Return | S&P 500 |
|---|---|---|
| 1m | +5.9% | +0.9% |
| 3m | +8.8% | +3.4% |
| 6m | +176.4% | +14.4% |
| 1y | +91.3% | +16.2% |
| ytd | +114.8% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HNGE Fundamental Analysis
Hinge Health's revenue trajectory is one of accelerating growth at scale: Q2 2026 revenue reached $212.8 million, up 53% year-over-year, building on Q1 2026 revenue of $182.3 million and Q4 2025 revenue of $170.7 million, which itself grew from $154.2 million in Q3 2025 and $139.1 million in Q2 2025. The sequential cadence ($139.1M → $154.2M → $170.7M → $182.3M → $212.8M) shows consistent quarter-over-quarter expansion with a notable step-up in Q2 2026, and the company operates as a single reportable segment, so the entire $212.8 million is driven by the core digital MSK platform. This growth profile — mid-50s percentage expansion on a revenue base approaching $1 billion annualized — implies the investment case rests on continued client wins and member engagement rather than pricing power, and any deceleration would pressure the premium multiple. Profitability has inflected decisively: Q2 2026 net income was $43.7 million with a 20.5% net margin, gross profit of $183.9 million on an 86.4% gross margin, and operating income of $40.4 million (19.0% operating margin), a dramatic reversal from the Q2 2025 loss of $575.7 million driven largely by a $591.0 million stock-based compensation charge tied to the IPO. Gross margin has expanded steadily from 70.3% in Q2 2025 to 84.6% in Q1 2026 to 86.4% in Q2 2026, and net margin has moved from -413.8% a year ago to +20.5% today, with the trailing valuation data showing a -89.9% net margin and -92.9% operating margin that reflect the IPO-period distortion rather than current run-rate economics. The balance sheet is exceptionally clean: debt-to-equity is just 0.021, the current ratio is 1.47, and the company generated $287.3 million in trailing twelve-month free cash flow against a $7.68 billion market cap (per the identity data) — though the key-metrics market cap of $3.68 billion implies a much higher FCF yield of roughly 7.8%. Q2 2026 operating cash flow was $101.4 million with capex of only $1.9 million, yielding $99.6 million of free cash flow, and the company repurchased $26.5 million of stock in the quarter while holding $287.7 million in cash, demonstrating self-funding growth with no reliance on external financing; ROE of -139.6% and ROA of 7.7% in the key metrics reflect trailing distortions, while the most recent quarterly historical ratios show ROE of 12.7% and ROA of 5.3%, consistent with a genuinely profitable business.
Quarterly Revenue
$212817000.0B
2026-06
Revenue YoY Growth
+53.0%
YoY Comparison
Gross Margin
86.4%
Latest Quarter
Free Cash Flow
$287327000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HNGE Overvalued?
Because Hinge Health reported positive trailing net income in its most recent quarters (Q2 2026 net income of $43.7 million), the PE ratio is the appropriate primary metric, but the trailing PE of -8.67x is negative and distorted by the IPO-period loss, so the forward PE of 31.9x is the more meaningful anchor; the gap between the distorted trailing figure and the 31.9x forward multiple implies the market is capitalizing normalized, post-IPO earnings power rather than the noisy trailing result. The forward PE of 31.9x against estimated EPS of $5.29 (average) suggests investors are paying a growth premium for a company expected to roughly double earnings from current run-rate levels, and the PS ratio of 6.26x and EV/Sales of 10.44x provide cross-checks on the revenue-based valuation. Peer comparison is constrained because the provided valuation data does not include an explicit industry-average PE or PS benchmark, so a precise premium/discount spread cannot be quantified; however, a 31.9x forward PE and 6.3x PS for a company growing revenue 53% with 86% gross margins and 20% net margins is consistent with a premium software-like multiple rather than a traditional healthcare services multiple, which appears justified by the growth and margin profile but leaves little room for execution error. Historically, HNGE's own PS ratio has compressed dramatically: it was 41.96x in Q2 2023, 35.43x in Q1 2024, 29.12x in Q3 2024, 25.10x in Q3 2025, and now 6.26x on the key-metrics basis, reflecting both the revenue ramp and the post-IPO multiple normalization; the PB ratio of 9.72x is well below the 18.99x recorded in Q2 2026 historical ratios, and the forward PE of 31.9x versus the Q2 2026 historical PE of 37.7x suggests the stock is now valued at a modest discount to its own recent earnings multiple. The PEG ratio of -0.002 is not meaningful due to the trailing loss distortion, but the forward earnings-based framing indicates the market is pricing in optimistic but not euphoric expectations, with the primary risk being multiple compression if growth decelerates below the 50%+ pace.
PE
-8.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 6x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-6.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are relatively contained given HNGE's strong balance sheet (debt-to-equity of 0.021, current ratio of 1.47) and robust free cash flow ($287.3M TTM). However, the company's valuation is heavily dependent on continued rapid growth; a deceleration from 53% YoY to, say, 30% would likely compress the forward PE from 31.9x to the low 20s, implying a 30-40% downside. Additionally, while gross margins are high at 86.4%, operating margins of 19.0% could face pressure if sales and marketing expenses (already 38% of revenue in Q2 2026) rise to capture new clients in a competitive landscape. The company's single-segment focus on digital MSK also concentrates risk; any clinical setback, regulatory change, or shift in employer health benefit design could disproportionately impact results.
Market and competitive risks are significant. The digital MSK space is attracting intense competition from both established healthcare players and new entrants, which could erode HNGE's pricing power and member acquisition efficiency. The stock's premium valuation (6.26x PS, 10.44x EV/Sales) leaves it vulnerable to sector rotation, especially if interest rates remain elevated and growth stocks fall out of favor. With a beta not reported, the stock's volatility is evident from its -48.03% max drawdown and 150.6% six-month rally, indicating high sensitivity to sentiment shifts. Recent news highlights the competitive threat: Zacks' September 2026 note warns that 'competition in digital health remains fierce' and that growth is 'already priced in,' suggesting limited margin for error.
In a worst-case scenario, a combination of decelerating revenue growth (e.g., to 20-30% YoY), margin compression from higher customer acquisition costs, and a broader market de-rating of high-multiple healthcare tech stocks could drive HNGE back toward its 52-week low of $30.08, representing a 69.2% decline from the current price of $97.67. The analyst low target of $90 implies a more modest -7.9% downside, but in a severe bear case, the stock could retest the $60-70 range (a 28-39% drop) if growth stalls and the forward PE compresses to 20x. Investors should be prepared for significant volatility given the stock's history of a -48% drawdown within the past year.
FAQ
The key risks include: (1) Growth deceleration: revenue growth falling below 40% would likely compress the multiple, as the stock trades at 31.9x forward earnings. (2) Competitive pressure: the digital MSK space is crowded, and increased competition could raise customer acquisition costs and pressure margins. (3) Valuation risk: the stock is near its 52-week high and has a history of a -48% drawdown, making it vulnerable to sharp reversals. (4) Macro sensitivity: a slowdown in employer spending on digital health benefits could impact client additions. These risks are ranked from highest to lowest severity.
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $130-140, assuming sustained 50%+ growth and multiple expansion. Base case (55% probability) targets $105-115, assuming growth moderates to 35-45% and margins improve. Bear case (20% probability) targets $60-90, assuming growth decelerates to 20-30% and the multiple compresses. The base case is most likely, supported by the analyst average target of $109.31 and consensus revenue estimates of ~$2.0B. The key assumption is that HNGE maintains its competitive edge and continues to expand profitability.
HNGE appears fairly valued to slightly overvalued. The forward PE of 31.9x is a premium to the broader healthcare sector, but it is justified by 53% revenue growth and 86.4% gross margins. The PS ratio of 6.26x is below the company's historical average (e.g., 25.1x in Q3 2025), reflecting multiple normalization post-IPO. Compared to peers, the valuation is rich but not unreasonable for a high-growth, profitable digital health company. The market is pricing in continued execution, so any deceleration could lead to multiple compression.
HNGE is a good buy for growth-oriented investors who can tolerate volatility. The company grew revenue 53% YoY in Q2 2026 to $212.8M, with a 20.5% net margin and $287.3M in trailing free cash flow. The analyst consensus is 'buy' with an average target of $109.31, implying 11.9% upside, though the high target of $140 suggests more potential. However, the stock trades at a premium 31.9x forward PE and has a history of a -48% drawdown, so it's not suitable for risk-averse investors. A pullback to the $85-90 support zone would offer a more attractive entry point.
HNGE is more suitable for long-term investment (minimum 2-3 years) given its early growth stage, high volatility (max drawdown of -48% in the past year), and lack of dividend. The company's strong fundamentals and large addressable market in digital MSK care support a multi-year growth trajectory. Short-term trading is risky due to the stock's sharp swings and dependence on quarterly earnings. Investors should have a time horizon of at least 2-3 years to ride out potential volatility and allow the company to scale and prove the sustainability of its margins.
